☆ 4.7 Article

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Microbiology

Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models

Haiting Liu et al.

Summary: Linezolid (LZD) is the first oxazolidinone approved for drug-resistant tuberculosis treatment. The BPaL regimen, combining LZD with bedaquiline (BDQ) and pretomanid (PMD), is an effective 6-month oral regimen against multidrug- and extensively drug-resistant tuberculosis. However, the toxicity of LZD due to mitochondrial protein synthesis inhibition may reduce its efficacy, and a safer and more effective alternative is needed. OTB-658, derived from LZD, shows better anti-TB activity and safety and could potentially replace LZD in TB treatment regimens.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Add to Collection

Article Microbiology

Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinam de Combination Regimen in a Murine Model of Tuberculosis

Yangming Ding et al.

Summary: TBI-166, derived from riminophenazine analogues, is a more potent anti-TB drug than clofazimine and is currently being tested in a phase IIa clinical trial in China. The results of this study demonstrate the superior efficacy of the TBI-166+BDQ+PZA regimen in treating murine TB models, compared to other regimens such as HRZ, TBI-166+BDQ+LZD, and BPaL. These findings suggest that TBI-166, in combination with BDQ and PZA, could be a promising treatment option for drug-resistant TB and should be further evaluated in phase IIb clinical trials.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Lenaig Tanneau et al.

Summary: This study investigated the relationship between plasma concentrations of delamanid and bedaquiline and the prolongation of QT interval corrected using Fridericia's formula (QTcF). The study found that the metabolites of each drug were responsible for the drug-related QTcF prolongation. The combination of the two drugs had a close to additive effect. The study also predicted that simplified, once-daily dosing regimens would have a similar QT prolonging potential compared to the approved regimens.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Pharmacology & Pharmacy

An Improved Method for Cytochrome P450 Reaction Phenotyping Using a Sequential Qualitative-Then-Quantitative Approach

Angela C. Doran et al.

Summary: Cytochrome P450 reaction phenotyping is a crucial method for predicting drug-drug interactions and interpatient variability in drug exposure. However, current recommended practices often fail to provide reliable estimates of fractional contributions (fm) of specific P450 enzymes to drug clearance. This study introduces a two-step qualitative-then-quantitative approach that yields more accurate fm estimates.

DRUG METABOLISM AND DISPOSITION (2022)

Add to Collection

Article Pharmacology & Pharmacy

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy

Linhu Ye et al.

Summary: This study demonstrated that XYPI injection affects the pharmacokinetics of LPV/RTV, especially the impact on RTV was significant, suggesting potential herb-drug interactions that clinicians and patients need to be aware of during COVID-19 treatment.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature

Camille Lenoir et al.

Summary: Inflammation has a specific impact on CYP activities, depending on the nature and severity of the underlying inflammatory disease. The drug-disease interactions can significantly affect drug pharmacokinetic parameters and clinical management. Resolution of inflammation may lead to normalization of CYP activity, but further research is needed to clarify some equivocal results.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Microbiology

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Precious Ngwalero et al.

Summary: The study used LC-MS/MS to measure intracellular concentrations of bedaquiline and its metabolite M2 in RR-TB patients in South Africa, finding that M2 accumulated at significantly higher concentrations intracellularly than bedaquiline. The intracellular-plasma accumulation ratio for bedaquiline and M2 is expected to reach maximum effect after 2 months of treatment.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists

Sirimas Sudsakorn et al.

CURRENT DRUG METABOLISM (2020)

Add to Collection

Article Microbiology

In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis

Jian Xu et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Atipamezole is a promising non-discriminative inhibitor against pan-CYP450 including diclofenac 4′-hydroxylation: A comparison with ABT for drug ADME optimization and mechanism study

Zheng Li et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)

Add to Collection

Article Microbiology

Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo

Ye Zhang et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Chemistry, Medicinal

Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging

Yang Li et al.

DRUG DEVELOPMENT RESEARCH (2019)

Add to Collection

Article Pharmacology & Pharmacy

Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s

Bo Lindmark et al.

BRITISH JOURNAL OF PHARMACOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches

Ramachandra Sangana et al.

DRUG METABOLISM AND DISPOSITION (2018)

Add to Collection

Article Chemistry, Multidisciplinary

CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats

Ye Xu et al.

ACTA PHARMACOLOGICA SINICA (2018)

Add to Collection

Article Infectious Diseases

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis

Margreke J. E. Brill et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)

Add to Collection

Article Pathology

Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs

Ilham Smyej et al.

TOXICOLOGIC PATHOLOGY (2017)

Add to Collection

Article Infectious Diseases

Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB

Mishal Pandie et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

Add to Collection

Article Microbiology

Comparative Study of the Effects of Antituberculosis Drugs and Antiretroviral Drugs on Cytochrome P450 3A4 and P-Glycoprotein

Yasuhiro Horita et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)

Add to Collection

Review Infectious Diseases

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

R. P. G. van Heeswijk et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)

Add to Collection

Article Pharmacology & Pharmacy

Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis

Brahim Achour et al.

DRUG METABOLISM AND DISPOSITION (2014)

Add to Collection

Article Pharmacology & Pharmacy

Bedaquiline Metabolism: Enzymes and Novel Metabolites

Ke Liu et al.

DRUG METABOLISM AND DISPOSITION (2014)

Add to Collection

Article Microbiology

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Elin M. Svensson et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

Add to Collection

Article Microbiology

Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation

Yu Lu et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)

Add to Collection

Article Pharmacology & Pharmacy

Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450

Yuan Chen et al.

DRUG METABOLISM AND DISPOSITION (2011)

Add to Collection

Article Biochemical Research Methods

Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery

Ben-Fillippo Krippendorff et al.

JOURNAL OF BIOMOLECULAR SCREENING (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.